HTGM:NSD-HTG Molecular Diagnostics, Inc (USD)

COMMON STOCK | Diagnostics & Research | NSD

Last Closing Price

USD 0.34

Change

+0.01 (+4.27)%

Market Cap

USD 0.02B

Volume

3.90M

Average Target Price

USD 1.40 (+309.36%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

HTG Molecular Diagnostics, Inc. a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's assay product offerings include HTG EdgeSeq oncology biomarker panel; HTG EdgeSeq immuno-oncology assay; HTG EdgeSeq DLBCL Cell of Origin Assay; HTG EdgeSeq PATH Assay; HTG EdgeSeq miRNA Whole-Transcriptome Assay; HTG EdgeSeq DLBCL Cell of Origin Assay EU; HTG EdgeSeq ALKPlus Assay EU; HTG EdgeSeq EGFR, KRAS and BRAF Mutation Assay; and HTG EdgeSeq Precision Immuno-Oncology Panel. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company has a collaboration agreement with Bristol-Myers Squibb for the development of custom RUO assays; governing agreement with QIAGEN Manchester Limited; development and professional services agreement with Invetech PTY Ltd; and an agreement with Illumina, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-03-27 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ILMN Illumina, Inc

-5.37 (-1.96%)

USD37.36B 37.71 27.99
DXCM DexCom, Inc

+12.75 (+5.10%)

USD19.19B 190.45 99.34
IDXX IDEXX Laboratories, Inc

+1.37 (+0.59%)

USD17.49B 41.92 25.40
EXAS Exact Sciences Corporation

-2.99 (-4.91%)

USD8.57B N/A -79.91
ICLR ICON Public Limited Company

-1.74 (-1.27%)

USD7.33B 20.14 13.70
GH Guardant Health, Inc

-3.34 (-4.70%)

USD5.66B N/A -74.02
SYNH Syneos Health, Inc

-2.32 (-5.28%)

USD4.58B 35.14 12.40
PRAH PRA Health Sciences, Inc

-1.36 (-1.70%)

USD4.55B 19.46 11.02
NEOG Neogen Corporation

-0.81 (-1.36%)

USD2.96B 50.14 34.49
NEO NeoGenomics, Inc

-1.54 (-5.65%)

USD2.70B 321.38 57.18

ETFs Containing HTGM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -51.28% 16% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -51.28% 16% F 14% F
Trailing 12 Months  
Capital Gain -86.15% 7% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -86.15% 7% F 4% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -13.35% 31% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -13.35% 31% F 19% F
Risk Return Profile  
Volatility (Standard Deviation) 64.81% 22% F 14% F
Risk Adjusted Return -20.60% 36% F 26% F
Market Capitalization 0.02B 14% F 17% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.69 93% A 75% C
Price / Cash Flow Ratio N/A N/A N/A N/A N/A
EV/EBITDA 0.40 50% F 60% D-
Management Effectiveness  
Return on Equity -66.93% 36% F 18% F
Return on Invested Capital -61.56% 28% F 15% F
Return on Assets -21.80% 39% F 20% F
Debt to Equity Ratio 28.67% 69% D+ 56% F
Technical Ratios  
Short Ratio 1.67 73% C 67% D+
Short Percent 9.26% 30% F 29% F
Beta 1.33 36% F 31% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector